Anti-proliferative and pro-apoptotic activity of GD2 ganglioside-specific monoclonal antibody 3F8 in human melanoma cells
Open Access
- 2 April 2015
- journal article
- research article
- Published by Taylor & Francis in OncoImmunology
- Vol. 4 (8) , e1023975
Abstract
The beneficial clinical effects of immunotherapy with GD2-specific monoclonal antibodies (mAbs) in melanoma and neuroblastoma patients have stimulated interest in characterizing the mechanisms underlying their antitumor effects. Previous studies have shown that GD2-specific mAbs mediate complement- and cell-dependent cytotoxicity and induce caspase-dependent apoptosis of tumor cells. In this study, we showed that GD2-specific mAb 3F8, which is undergoing clinical evaluation, inhibited the in vitro growth and induced apoptosis of melanoma cells. This effect was dose- and time-dependent, mediated by the interaction of mAb 3F8 combining site with GD2 ganglioside, associated with GD2 expression level on the cell surface, mAb internalization and increase of GD2 containing endosomes triggered by mAb 3F8. The induction of apoptosis by mAb 3F8 was mediated by caspase 3-, 7-, and 8-dependent pathways, downregulation of the anti-apoptotic molecules survivin and cytochrome c, and caspase 9 independent-AIF release from mitochondria. In addition, analyses of signaling pathway components demonstrated that mAb 3F8 strongly inhibited AKT and FAK activation and increased cleaved PARP expression. These results indicated that multiple mechanisms played a role in the antitumor activity of mAb 3F8 in melanoma cells. This information should provide a mechanistic basis for the optimization of the rational design of immunotherapeutic strategies in the mAb-based treatment of GD2 positive tumors.Keywords
This publication has 39 references indexed in Scilit:
- CSPG4 Protein as a New Target for the Antibody-Based Immunotherapy of Triple-Negative Breast CancerJNCI: Journal of the National Cancer Institute, 2010
- Apaf-1 expression in malignant melanomaCell Death & Differentiation, 2005
- Cellular and molecular signal transduction pathways modulated by rituximab (rituxan, anti-CD20 mAb) in non-Hodgkin's lymphoma: implications in chemosensitization and therapeutic interventionOncogene, 2005
- Decreased expression of Apaf‐1 with progression of melanomaPigment Cell Research, 2005
- An Anti‐GD2 Monoclonal Antibody Enhances Apoptotic Effects of Anti‐cancer Drugs against Small Cell Lung Cancer Cells via JNK (c‐Jun Terminal Kinase) ActivationJapanese Journal of Cancer Research, 2002
- Pharmacokinetics of anti-ganglioside GD2 mAb 14G2a in a phase I trial in pediatric cancer patientsCancer Immunology, Immunotherapy, 1995
- Antitumor effects of a novel monoclonal antibody with high binding affinity to ganglioside GD3Cancer Immunology, Immunotherapy, 1993
- Disialoganglioside GD2 anti‐idiotypic monoclonal antibodiesInternational Journal of Cancer, 1993
- Gangliosides of human melanomaCancer, 1989
- Ganglioside GD2 specificity of monoclonal antibodies to human neuroblastoma cellBiochemical and Biophysical Research Communications, 1985